Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a clinical-stage biotechnology company whose news flow centers on the development of investigational cancer therapies. The company regularly issues updates on its lead CD47 inhibitor, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004, as these programs advance through clinical and preclinical milestones.
News about ALX Oncology often covers clinical trial progress for evorpacept in HER2-positive gastric and gastroesophageal cancers, HER2-positive metastatic breast cancer and indolent B-cell non-Hodgkin lymphoma. Press releases detail study designs, enrollment status, biomarker findings such as CD47 overexpression as a potential predictive biomarker, and data presented at major oncology and immunotherapy conferences, including meetings of the Society for Immunotherapy of Cancer (SITC), the American Society of Hematology (ASH) and the European Society for Medical Oncology (ESMO).
For ALX2004, company announcements highlight preclinical data, poster presentations at scientific conferences such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and updates from the ongoing Phase 1 first-in-human trial in EGFR-expressing solid tumors. These items typically describe dose-escalation progress, safety observations and the rationale for further clinical evaluation.
ALX Oncology also reports quarterly financial results and corporate updates via press releases and related conference calls, which are referenced in Current Reports on Form 8-K. Additional news may include participation in investor conferences, webcasts, and changes in leadership or board composition. Readers who follow ALXO news can use this page to track clinical milestones, data disclosures and corporate developments over time.
ALX Oncology (ALXO) announced a virtual event scheduled for January 23, 2025, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from their ASPEN-06 Phase 2 clinical trial. The trial evaluates evorpacept, their CD47-blocker, in patients with previously treated HER2-positive advanced gastric cancer or gastroesophageal junction cancer.
The data will be presented earlier the same day at the 2025 ASCO GI Symposium in a Rapid Oral Abstract Session. Dr. Kohei Shitara, Director of Gastrointestinal Oncology at National Cancer Center Hospital East in Japan, will present the final analysis of the randomized phase 2 part of the study. The presentation is scheduled for 9:15 a.m. – 10:00 a.m. PT.
ALX Oncology Holdings (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing immune system-boosting cancer therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Jason Lettmann will present a company overview on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time.
The presentation will be accessible via live webcast through a direct link and the Investors section of ALX Oncology's website under the Events section of the News and Events tab. A replay of the presentation will remain available for up to 30 days after the event.
ALX Oncology (Nasdaq: ALXO) announced that updated results from its Phase 2 ASPEN-06 clinical trial will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. The trial evaluates evorpacept, a CD47-blocking therapeutic, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel for treating HER2-positive gastric/gastroesophageal junction cancer patients who previously received anti-HER2 therapy.
The presentation will be delivered by Dr. Kohei Shitara from the National Cancer Center Hospital East in Japan on January 23, 2025. The study results will be presented during the Rapid Oral Abstract Session focusing on Cancers of the Esophagus and Stomach.
ALX Oncology (ALXO) announced a virtual event scheduled for December 17, 2024, at 8:00 AM EST to discuss new clinical data from their Phase 1b/2 trial. The trial evaluates evorpacept, their CD47-blocker, in combination with Jazz Pharmaceuticals' zanidatamab for treating heavily pretreated patients with metastatic breast cancer. The data was presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).
The event will feature Dr. Alberto J. Montero, Clinical Director of Breast Cancer Medical Oncology at University Hospitals Seidman Cancer Center, who will present the data and participate in a fireside chat with ALX's Chief Medical Officer, Dr. Alan Sandler. CEO Jason Lettmann will discuss the company's progress and upcoming milestones for the evorpacept program.
ALX Oncology (Nasdaq: ALXO) announced promising results from a Phase 1b/2 clinical trial evaluating evorpacept in combination with zanidatamab for HER2-positive breast cancer. The study showed significant efficacy in heavily pretreated patients, with a 55.6% confirmed objective response rate and 7.4 months median progression-free survival in HER2-positive patients by central assessment.
The trial included three cohorts: HER2-positive breast cancer patients (n=21), HER2-low breast cancer patients (n=15), and other HER2-expressing cancers (n=8). Most treatment-related adverse events were grade 1 or 2, with common effects including fatigue, nausea, diarrhea, and infusion-related reactions. No treatment-related deaths or non-infectious pulmonary toxicities were reported.
ALX Oncology (Nasdaq: ALXO) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City. CEO Jason Lettmann will engage in a fireside chat with analyst Christopher Raymond on December 3, 2024, at 9:30 AM EST. The event will also include one-on-one meetings.
The fireside chat will be accessible via webcast through ALX Oncology's website investor section, with a replay available for up to 90 days following the event. ALX Oncology is a clinical-stage biotechnology company focused on developing immune system-boosting cancer therapies to extend patient lives.
ALX Oncology Holdings (Nasdaq: ALXO) has appointed Alan Sandler, M.D. as Chief Medical Officer. Dr. Sandler brings over 30 years of experience in oncology and drug development, having previously served as Executive Vice President and CMO at Mirati Therapeutics, President and Global Head of Development in Oncology at Zai Lab, and Senior Vice President at Genentech. He will lead the clinical development of evorpacept, the company's investigational lead compound, into late-stage clinical trials. Dr. Sandler, who previously served on ALX Oncology's Board of Directors, has co-authored over 300 publications and holds an M.D. from Rush Medical College.
ALX Oncology (NASDAQ: ALXO) reported Q3 2024 financial results and clinical progress. The company's lead candidate evorpacept showed promising results in the ASPEN-06 Phase 2 trial, achieving a 40.3% overall response rate compared to 26.6% in the control arm for HER2-positive gastric cancer treatment.
Financial highlights include cash position of $162.6 million, sufficient until Q1 2026. Q3 net loss was $30.7 million ($0.58 per share), improved from $51.0 million loss year-over-year. R&D expenses decreased to $26.5 million from $45.8 million, while G&A expenses reduced to $6.1 million from $7.5 million.
ALX Oncology (Nasdaq: ALXO) announced its participation in two upcoming investor conferences in November 2024. The company will participate in the UBS Global Healthcare Conference on November 12 at 3:30 PM PST in Rancho Palos Verdes, CA, featuring a fireside chat with analyst Trung Huynh. Additionally, they will attend the Jefferies London Healthcare Conference on November 19 at 9:00 AM GMT in London, with analyst Michael Yee. Both events will include 1x1 meetings and webcasts accessible through ALX Oncology's website, with replays available for up to 90 days.
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from their two-part, open-label, multicenter study (NCT05027139) evaluating evorpacept, a CD47 blocker, combined with zanidatamab, a dual HER2-targeted bispecific antibody. Dr. Alberto J. Montero from University Hospitals Seidman Cancer Center will present the findings on December 12, 2024.